ARTICLE | Company News
The Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY) declined to exercise its exclusive option to obtain ex-U.S. rights to VY-AADC-01 from Voyager Therapeutics Inc. (NASDAQ:VYGR) to treat Parkinson’s disease.
According to Voyager, Genzyme decided to opt out because its option did not include U.S. rights. Sanofi spokesperson Anna Robinson told BioCentury that it made the decision for “strategic reasons,” without elaborating on the company's thinking...